Nilutamid
 | |
| Klinički podaci | |
|---|---|
| Prodajno ime | Anandron, Nilandron, Nilandrone, Nilutamida [Spanish] |
| Drugs.com | Monografija |
| Način primene | Oralno |
| Farmakokinetički podaci | |
| Poluvreme eliminacije | 38,0-59,1 h |
| Identifikatori | |
| CAS broj | 63612-50-0  |
| ATC kod | L02BB02 (WHO) |
| PubChem | CID 4493 |
| IUPHAR/BPS | 2864 |
| DrugBank | DB00665 |
| ChemSpider | 4337 |
| KEGG | C08164 |
| ChEBI | CHEBI:7573 |
| ChEMBL | CHEMBL1274 |
| Hemijski podaci | |
| Formula | C12H10F3N3O4 |
| Molarna masa | 317,221 |
| |
| |
Nilutamid je organsko jedinjenje, koje sadrži 12 atoma ugljenika i ima molekulsku masu od 317,221 Da.[1][2][3][4]
Osobine[uredi | uredi izvor]
| Osobina | Vrednost |
|---|---|
| Broj akceptora vodonika | 4 |
| Broj donora vodonika | 1 |
| Broj rotacionih veza | 3 |
| Particioni koeficijent[5] (ALogP) | 2,3 |
| Rastvorljivost[6] (logS, log(mol/L)) | -5,0 |
| Polarna površina[7] (PSA, Å2) | 95,2 |
Reference[uredi | uredi izvor]
- ^ Kassouf W, Tanguay S, Aprikian AG: Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. J Urol. 2003 May;169(5):1742-4. PMID 12686822
- ^ Lukka H, Waldron T, Klotz L, Winquist E, Trachtenberg J: Maximal androgen blockade for the treatment of metastatic prostate cancer--a systematic review. Curr Oncol. 2006 Jun;13(3):81-93. PMID 17576447
- ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709
. PMID 21059682. doi:10.1093/nar/gkq1126.
- ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
- ^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o.
- ^ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
- ^ Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714—3717. PMID 11020286. doi:10.1021/jm000942e.
Literatura[uredi | uredi izvor]
- Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
- Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.
Spoljašnje veze[uredi | uredi izvor]
 | Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |
